´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2023-09-22
±³À°ÀÏÀÚ : 2023-09-22
±³À°Àå¼Ò : ´ë±¸, ¿¢½ºÄÚ
±³À°ÁÖÁ¦ : KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ : ksn@ksn.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 22 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í "[»çÀüµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-20,000/ÀüÀÏ50,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-10,000¿ø/ÀüÀÏ-20,000¿ø
[ÇöÀåµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-30,000/ÀüÀÏ60,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-15,000¿ø/ÀüÀÏ-30,000¿ø *¸¸65¼¼ÀÌ»óȸ¿ø, Çлý-¸éÁ¦"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:00~09:25 Incidence and Characteristics of Renal Cell Carcinoma in ADPKD patients ¹ÚÇýÀÎÁ¶(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:25~09:50 Recent updates in tolvaptan treatment based on the guidelines ±è¿¹¸²(°è¸íÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 09:50~10:15 Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice Á¤¿¬¼ø(°í½ÅÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 10:15~10:40 ADPKD ȯÀÚ¿¡¼ ¿µ¾ç°ü¸® ¿ÀÀ±±Ô(¼¿ïÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room1 10:40~10:50 ÁúÀÇ ÀÀ´ä ()
ÈÞ½Ä 09¿ù 22ÀÏ Room1 10:50~11:00 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:00~11:20 Tolvaptan in children with ADPKD or ARPKD Á¶¹ÎÇö(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:20~11:40 Nephrogenic DI or other hyponatremic condition ¼Áø¼ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 11:40~12:00 ENT manifestations of Alport syndrome ÀÌ»ó¿¬(¼¿ïÀÇ´ë )
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 12:00~12:20 Ophthalmologic manifestations of Alport syndrome Á¤ÀçÈ£(¼¿ïÀÇ´ë )
Åä·Ð 09¿ù 22ÀÏ Room1 12:20~12:50 ÁúÀÇ ÀÀ´ä ()
½Ä»ç 09¿ù 22ÀÏ Room1 12:50~13:50 ½Ä»ç ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 13:50~14:15 Nutrition & muscle wasting in patients with AKI undergoing CRRT ±è¿ìÁ¤(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 14:15~14:40 Protein diet & muscle wasting in patients with CKD °í°Áö(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room1 14:40~14:45 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 14:45~15:10 Mitochondrial dysfunction & Sarcopenia ÀüÀçÇÑ(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 15:10~15:35 Gut-muscle crosstalk in CKD Â÷¶õÈñ(±¹¸³ÀÇ·á¿ø)
Åä·Ð 09¿ù 22ÀÏ Room1 15:35~15:40 ÁúÀÇ ÀÀ´ä ()
ÈÞ½Ä 09¿ù 22ÀÏ Room1 15:40~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 15:50~16:15 Open label, randomized comparative multicenter clinical trial on the clinical effect of online education program in patient with chronic kidney disease Á¤¹®°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 16:15~16:40 Adaptive nutrition intervention stabilizes serum phosphorus levels in hemodialysis patients: a multi-center decentralized clinical trial using real-world data ±è°æ¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 16:40~17:05 The current and future landscape of hemodialysis data management °û»óÇõ(°û»óÇõ³»°ú)
±³À°½Ã°£ 09¿ù 22ÀÏ Room1 17:05~17:30 Smart contract-enabled decentralized clinical research for hemodialysis patients ±èÁÖÇÑ(¼¿ïÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room1 17:30~17:40 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:00~09:25 Understanding roles of thin limbs of the kidney Çѱâȯ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:25~09:50 Circadian regulation of renal sodium handling ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 09:50~10:10 Mornining vs. evening dosing of antihypertensive medications ¼»óÇå(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 10:10~10:30 Discontinuing renin-angiotensin system blockades in advanced chronic kidney disease ¹é¼±ÇÏ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 10:30~10:50 Chlorthalidone vs. hydrochlorothiazide on cardiovascular and renal outcomes ¹èÀºÁø(°æ»óÀÇ´ë)
ÈÞ½Ä 09¿ù 22ÀÏ 10:50~11:00 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:00~11:20 Pathophysiology in anemia among AKI patients ¾ÈÁ¤³²(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:20~11:40 Considerations in therapeutic strategy in anemia of AKI patients ¾çÁöÇö(¼º±Õ°üÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room2 11:40~11:55 ÆгÎÅäÀÇ ÀÌÁ¤È¯, ±èµµÇü, ÀÌÇØ°æ(¼¿ïÀÇ´ë, ÇѸ²ÀÇ´ë, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 11:55~12:15 Pros in HIF-PHD stabilizer among CKD patients ȲÇö¼®(°æÈñÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 12:15~12:35 Cons in HIF-PHD stabilizer among CKD pateints ±èÁöÀº(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room2 12:35~12:50 ÆгÎÅäÀÇ ÀÌÁ¤Ç¥, À±ÇØ·æ, ¾È½Å¿µ(¼¿ïÀÇ´ë, ¿¬¼¼ÀÇ´ë, °í·ÁÀÇ´ë)
½Ä»ç 09¿ù 22ÀÏ 12:50~13:50 ½Ä»ç ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 13:50~14:15 Åõ¼® Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ºóÇ÷ °ü¸® À±¿µ¹Î(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 14:15~14:40 Ç÷¾×Åõ¼®ÀÌ ¿¹»óµÇ´Â ȯÀÚÀÇ Åõ¼® Á¢±Ù·Î È®º¸ ÀÌÇÏÀº(ÀüÁÖ¿¹¼öº´¿ø)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 14:40~15:05 Åõ¼® Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ½ÄÀÌ °ü¸® ¿°ÁöÇö(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 15:05~15:30 Åõ¼®Àü ¸¸¼ºÄáÆϺ´ ȯÀÚÀÇ ¾à¹°Ä¡·áÀÇ ÃÖ½ÅÁö°ß Á¤Á¾È¯(¿ø±¤ÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room2 15:30~15:40 ÁúÀÇ ÀÀ´ä ()
ÈÞ½Ä 09¿ù 22ÀÏ 15:40~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 15:50~16:10 Optimal Management of CKD-MBD, Focusing on the New Iron-based Phosphate Binder Ȳ¼±´ö(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:10~16:30 New Therapeutic Agent for IgA Nephropathy: Nefecon (targeted-release formulation-budesonide) ±èÂùÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:30~16:50 The Use of Anti-BAFF Therapy in Kidney Diseases ¹ÎÁö¿ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 16:50~17:10 Novel Therapies for Alport Syndrome À½»óÈÆ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room2 17:10~17:30 Mitochondrial Targeted Antioxidants as a Complementary Treatment Strategy À¯º´Ã¶(¼øõÇâÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room2 17:30~17:40 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:00~09:25 Role of the calcium-sensing receptor & FGF receptor in CKD-MBD ¾È½Å¿µ(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 09:25~09:30 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:30~09:50 Role of the vitamin D receptor in CKD-MBD ±èÁöÀº(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 09:50~09:55 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 09:55~10:15 Role of the type 2 sodium-dependent phosphate cotransporters in CKD-MBD ±èÀ±¹Ì(ºÎ»ê¹éº´¿ø)
Åä·Ð 09¿ù 22ÀÏ Room3 10:15~10:20 ÁúÀÇ ÀÀ´ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 10:20~10:45 Role of the RANK/RANKL/OPG and Wnt/¥â‑Catenin Systems in CKD-MBD ¾È¼ºÈñ(ÀÎÇÏÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 10:45~10:50 ÁúÀÇ ÀÀ´ä ()
ÈÞ½Ä 09¿ù 22ÀÏ 10:50~11:00 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:00~11:25 ü¾×·®°ú ±ÙÀ° °¨¼ÒÁõ °¼®ÈÖ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:25~11:50 Hemodiafiltration or Expanded hemodialysis? ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 11:50~12:15 warfarin vs. NOAC ±è¼º±Ô(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 12:15~12:40 ¹Ýº¹µÇ´Â ÆóºÎÁ¾ ȯÀÚ, ¾î¶»°Ô Çϳª¿ä? ¹éÁøÇõ(°è¸íÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 12:40~12:50 ÆгÎÅäÀÇ °°Ç¿ì, ±ÇÇõ¸¸(°¡Å縯 ¿¬ÇÕ³»°ú, ÇÑ°¡¶÷º´¿ø)
½Ä»ç 09¿ù 22ÀÏ 12:50~13:50 ½Ä»ç ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 13:50~14:15 Pretransplant heart disease testing and kidney transplant outcomes ±è¼¸°(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 14:15~14:40 Emerging evidence on coronary heart disease screening in kidney transplantation candidates Á¤Èñ¿¬(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 14:40~15:05 Paradigm shift in lifestyle modification for solitary kidney after donor nephrectomy ¿ÀÁؼ®(±è¿ø¹¬±â³äºÀ»ýº´¿ø)
Åä·Ð 09¿ù 22ÀÏ Room3 15:05~15:20 ½ÅÀÌ½Ä Áõ·Ê Åä·Ð 1 ÀÌÇöÁ¤(°è¸íÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 15:20~15:40 ½ÅÀÌ½Ä Áõ·Ê Åä·Ð 2 ¹Úº´È(°í½ÅÀÇ´ë)
ÈÞ½Ä 09¿ù 22ÀÏ 15:40~15:50 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 15:50~16:15 PPI associated nephrotoxicity À̽ÂÇý(°æ»óÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 16:15~16:40 Acute kidney injury in patients with liver cirrhosis ¹Ú½ÃÇü(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 16:40~17:05 Use of DOAC in hemodialysis patients ¾ÈÁ¤¸í(±è¿ø¹¬±â³ä)
±³À°½Ã°£ 09¿ù 22ÀÏ Room3 17:05~17:30 Nutritional intervention in eldery CKD patients ¾È¿ø¼®(µ¿¾ÆÀÇ´ë)
Åä·Ð 09¿ù 22ÀÏ Room3 17:30~17:40 ÁúÀÇ ÀÀ´ä ()